Nyrada (ASX: NYR) is down 54% this morning as it turns out that the cholesterol reducing drug they've been trying to develop actually poisons people who take it. Not that it's put in quite such stark terms but that's really what this message is: “: Nyrada Inc (ASX: NYR), a drug development company specialising in novel small molecule drugs to treat cardiovascular and neurological diseases, today announced that while the Company's cholesterol-lowering drug candidate returned no unusual safety signals in all but one key study, due to an adverse signal observed in a Good Laboratory Practice (GLP) toxicology study, the Company's drug candidate will not be taken forward into the planned Phase I/IIa clinical trial.”
This was all still at the stage of animal studies - and could be taken as a proof of the value of animal studies - but too many test subjects were popping their clogs as a result of taking the drug. Rather than only gaining that reduced cholesterol which was the aim of the exercise.
As a result of this Phase I/IIa trials will now not go forward. To translate that out of the jargon, that means the entire development so far is a bust. It could even be true that cholesterol is reduced by the drug but at an entirely unaccepable cost. So, no more development, write off all costs and everything done so far.

Nyrada stock price from ASX
Do note what's happening here - this is not a setback which will be recovered from. This particular line of inquiry is now closed.
This all being an excellent example of how pharma development companies work. There's a series of tests, hurdles, in the development of any drug or treatment. Passing one of them does not mean that everything's going to come up roses. It just allows the onward movement to trying to pass the next test. Only something that passes all of the tests will eventually come to market. The failure of any one of these tests means that's that, the end. Here it's a very early test that was failed. But some drugs do fail much later - and after much more money has been spent.
That's just the way the whole sector works. Every proposed new drug is tested to destruction and it can - and most do - fail at any one of these stages.